Shares of Edgewise Therapeutics, a biotech company developing drugs to treat muscular dystrophies, are driven by news from its clinical programs. The price chart reflects investor hopes for a breakthrough treatment for these devastating diseases.
Edgewise, a biotech developing drugs to treat muscular dystrophies, is driven by news from its clinical programs. We classify it in the Pharma Neurology sector, and the chart below shows the dynamics of this entire segment, where the price depends on the success of clinical trials.
Edgewise Therapeutics is a biopharmaceutical company developing drugs to treat rare muscle diseases by targeting muscle proteins. It is a component of the GURU.Markets index. The chart below represents the market. See how this company's stock compares to the overall biotech sector.
Shares of Edgewise Therapeutics, a biopharmaceutical company, exhibit high volatility, as measured by change_co. This indicator reflects sensitivity to news about clinical trials. This metric is a key component of the formulas on System.GURU.Markets for analyzing the biotech sector.
Edgewise Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with EWTX, which focuses on muscle disease treatments, helps to assess it as a high-risk, clinical-data-driven asset.
Edgewise is a biopharmaceutical company developing treatments for rare muscle diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Edgewise's stock performance.
Edgewise is a biotech company working on treatments for neurological diseases. Its shares represent a venture-backed bet on scientific success. Their high volatility, driven by expectations, contributes to the complex and multifaceted dynamics of the overall stock market.
Edgewise Therapeutics, Inc. is a clinical-stage biotech company developing drugs to treat rare muscle diseases. Its stock price is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Edgewise Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Edgewise, a biotech company developing drugs to treat rare muscle diseases, has sharp monthly fluctuations reflecting the release of clinical trial data, which is key to its valuation.
Edgewise Therapeutics is a clinical-stage biotech company developing oral medications for the treatment of rare muscle diseases such as Duchenne muscular dystrophy. The chart below illustrates the overall dynamics of the biotech sector, where the potential for treating rare diseases is attracting considerable attention.
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for the treatment of rare muscle diseases. The company's future depends on the success of its clinical trials. The broader market chart serves as a backdrop to demonstrate how news about its drugs has driven its stock price completely independently.
Shares of Edgewise Therapeutics, a biotech company focused on treating rare muscle diseases, are rising weekly to reflect progress in this complex field. The price movement is a response to clinical trial data that could offer hope to patients with devastating genetic disorders.
Neuroscience-focused biotech is a sector where weekly performance is driven by clinical data. The search for new treatments for rare muscle diseases is a common trend across all sectors. The chart illustrates this backdrop, which can be used to assess Edgewise Therapeutics' potential.
Edgewise Therapeutics develops drugs to treat muscle disorders. Shares of such innovative biotech companies often move independently of the market. This chart will help you understand: is Edgewise living in its own world of clinical trials, or are overall market conditions and risk appetite influencing its stock price?
Edgewise's market capitalization tells the story of a biotech company focused on developing drugs to treat rare muscle diseases. Its volatile price action reflects the company's clinical trial data. Its price action reflects investors' assessment of its drugs' potential to transform patients' lives and become a new standard of care.
Edgewise Therapeutics is a biotech company developing small-molecule drugs for the treatment of rare muscle diseases. Its market share reflects the potential of its innovative approach. Its market cap reflects the success of its clinical programs and the hope for new treatments for patients.
Edgewise Therapeutics is a clinical-stage biotech company developing drugs to treat rare muscle diseases. The chart below shows the overall market capitalization of this sector. Its volatility reflects investor hopes that science will offer new treatments for patients with severe diagnoses.
Edgewise Therapeutics develops small-molecule drugs to treat rare muscle diseases. Its market cap reflects the hope of developing targeted therapies to protect muscle tissue. The chart below shows the economic weight of biotech companies in this field.
Edgewise Therapeutics' balance sheet represents its capital invested in clinical trials of drugs for rare muscle diseases. This is a real, scientific foundation aimed at developing innovative therapies to improve muscle function. How has this biotech asset changed? The chart below shows its dynamics.
Edgewise Therapeutics develops drugs to treat muscle diseases, which requires modern research laboratories. The chart shows the share of these science-intensive tangible assets in the pharmaceutical sector, reflecting the physical foundation of its work on rare diseases.
Developing drugs to treat rare muscle diseases, as the BCap_Seg chart for biotech shows, is a science-intensive endeavor. Edgewise Therapeutics operates in this environment, investing its capital in clinical research and intellectual property rather than in plant construction.
Edgewise Therapeutics' assets are not product lines, but a valuable portfolio of intellectual property and clinical trial data in the field of muscle diseases. Its book value reflects capital invested in science, which forms the foundation for future, tangible drugs.
Edgewise Therapeutics is a clinical-stage biotech developing drugs to treat muscle disorders. Its balance sheet is funded by R&D. Its market cap is a bet on science. The MvsBCap chart will be highly volatile and unrelated to financial performance, depending entirely on news about the progress of clinical trials.
Edgewise Therapeutics is a biotech company developing drugs to treat rare muscle diseases. Its value is almost entirely dependent on the success of clinical trials. The chart reflects investor expectations for the future of its research.
Edgewise Therapeutics develops drugs to treat rare muscle diseases. Like other clinical-stage biotech companies, its market value is largely unrelated to its book value. It reflects investors' assessment of its scientific potential and the likelihood of success in treating serious diseases.
Edgewise Therapeutics, a clinical-stage biotech, is dedicating all of its raised capital to developing drugs for muscular dystrophies. Until product approval, the company relies entirely on external funding. This chart illustrates how the company manages its resources during the long and capital-intensive process of developing new treatments.
Edgewise Therapeutics is a biotech company specializing in developing treatments for rare muscle diseases. Funding expensive and lengthy clinical trials is a key challenge for companies at this stage. This chart may reflect how the company structures its capital to bring its innovative drugs to patients.
Edgewise Therapeutics is a biotech company developing drugs to treat rare muscle diseases. The chart shows how it finances its expensive clinical trials. For a company without stable revenue, debt is a significant risk, but it also demonstrates investors' faith in its scientific approach and the potential of future drugs.
Edgewise Therapeutics is a biotech company developing drugs to treat muscle diseases. This biotech chart shows how much capital the industry attracts to fund breakthrough but risky research. It helps understand how the company's financial position is typical for this science-intensive field.
Edgewise Therapeutics is a biotech company. Its funding depends on investors' confidence in its future drugs. This chart reflects the overall risk appetite in the economy. For a company without revenue, it helps understand how its debt- or equity-based financing model compares to the overall market.
A chart of Edgewise Therapeutics, a biopharmaceutical company targeting muscle diseases, shows how investors view its scientific breakthroughs. The high values reflect the high hopes that its drugs will offer effective treatments for patients with muscular dystrophy and other severe ailments.
This chart shows the average P/E for the biopharmaceutical industry in which Edgewise is developing. The sector's very high average valuation reflects hopes for scientific breakthroughs. The chart illustrates this general backdrop against which the potential of Edgewise's drugs for treating muscle disorders is assessed.
Edgewise Therapeutics develops small-molecule drugs to treat rare muscle diseases, targeting muscle fiber damage. This innovative scientific approach is key. This chart, reflecting overall risk appetite, helps us understand whether investors are willing to fund Edgewise's long journey from the lab to the market in hopes of creating a new standard of care.
Edgewise Therapeutics is a biotechnology company developing small-molecule drugs for the treatment of rare muscle diseases. The graph reflects speculative revenue expectations, which depend on the success of clinical trials and the potential of its therapy to become a new standard of care for patients with muscular dystrophies.
%20P%2FE%20Edgewise%20Therapeutics&width=1500&height=450&colorIndex=35&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Edgewise-Therapeutics "Chart of the company's future (projected) P/E Edgewise Therapeutics")
Edgewise Therapeutics develops small-molecule drugs to treat rare muscle diseases. The company aims to protect muscles from disease-related damage. The chart shows average profitability expectations for the sector, helping to understand the level of investor confidence in Edgewise's scientific approach and its commercial potential.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20&width=1500&height=450&colorIndex=36&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment "Future (projected) P/E graph of the market segment -")
Edgewise Therapeutics is a biotech company developing small-molecule drugs to treat rare muscle diseases. Its valuation depends on the success of clinical trials. This overall risk appetite chart shows how willing investors are to invest in long-term, risky biotech projects with very high potential returns.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole "Chart of the future (projected) P/E of the market as a whole")
Edgewise Therapeutics is a clinical-stage biotech company developing small-molecule drugs for the treatment of rare muscle diseases. Its financial metrics currently consist of R&D expenses. This chart shows the company's investment in research to develop potential breakthrough drugs.
Edgewise Therapeutics is a biotech company developing small-molecule drugs for the treatment of severe and rare neuromuscular diseases. Its approach is aimed at protecting muscles from damage. This chart illustrates the overall picture in the neurological pharmaceutical sector, where there is a huge need for new treatments, and scientific breakthroughs can change patients' lives.
Edgewise Therapeutics is a biotechnology company developing drugs to treat rare muscle diseases. Its prospects and value are determined solely by the results of clinical trials. The overall economic environment, illustrated by this chart, has no impact on the scientific process or patient demand for effective treatment.
Edgewise Therapeutics is a clinical-stage biotechnology company developing small-molecule drugs for the treatment of rare muscle diseases. Future revenue is entirely dependent on the success of clinical trials. This chart reflects analysts' speculative expectations regarding the scientific breakthrough and commercial potential of its developments.
%20profit%20of%20the%20company%20Edgewise%20Therapeutics&width=1500&height=450&colorIndex=41&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Edgewise-Therapeutics "Graph of future (projected) profit of the company Edgewise Therapeutics")
Edgewise Therapeutics is a biotech company developing oral medications for rare muscle diseases. Its innovative approach aims to protect muscle fibers from damage. The company's success depends on the results of clinical trials. This chart shows revenue projections for the pharmaceutical sector, providing context for assessing Edgewise's potential.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20&width=1500&height=450&colorIndex=42&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment "Graph of future (predicted) profits of companies in a market segment -")
Edgewise Therapeutics is a biotech company developing drugs to treat rare muscle diseases. Its valuation is determined by progress in clinical trials. This economic outlook affects overall investor risk appetite and the availability of funding for development-stage biotech companies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole "Chart of future (predicted) profits of the market as a whole")
Edgewise Therapeutics is a biotech company developing drugs to treat rare muscle diseases. The company has no revenue at the clinical stage. This chart reflects investor expectations for the success of its clinical programs. The company's performance is entirely dependent on scientific data.
Edgewise Therapeutics is a clinical-stage biopharmaceutical company developing oral medications for rare muscle diseases. Their innovative approach aims to protect muscles from damage caused by intense muscle contractions. This chart reflects the average revenue estimate for the sector, providing insight into market expectations for Edgewise's breakthrough science.
Edgewise Therapeutics is a clinical-stage biotech developing small-molecule drugs for rare muscle diseases. This chart highlights that the valuation of such companies is based not on current revenue but on the potential of their scientific discoveries, which contrasts sharply with the market average.
Edgewise Therapeutics is a biotechnology company developing small-molecule drugs for the treatment of rare muscle diseases. For a clinical-stage company whose success depends on research results, valuation based on future revenue is key. It reflects investors' confidence in the scientific potential of its developments and future commercial success should the drugs be approved.
%20P%2FS%20Edgewise%20Therapeutics&width=1500&height=450&colorIndex=47&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Edgewise-Therapeutics "The graph of the company's future (projected) P/S Edgewise Therapeutics")
Edgewise Therapeutics is a biotech company developing small-molecule drugs to treat rare muscle diseases, targeting muscle damage. This chart compares the company's estimated future sales with industry expectations. It shows how investors view the company's scientific approach and the potential of its candidates to transform patients' lives.
%20P%2FS%20market%20segment%20graph%20-%20&width=1500&height=450&colorIndex=48&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph "Future (projected) P/S market segment graph -")
Edgewise Therapeutics develops drugs to treat rare muscle diseases. It's a science-intensive, future-focused business. Revenue growth expectations, as shown in the graph, don't always take into account the potential for biotech breakthroughs that could create entirely new markets.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole "Chart of the future (projected) P/S of the market as a whole")
This chart shows the revenue of Edgewise Therapeutics, a clinical-stage biotech developing drugs to treat rare muscle diseases. Currently, commercial revenue is unlikely to be generated. Any revenue may be related to partnerships, and future growth depends on the success of clinical trials.
Edgewise Therapeutics is a clinical-stage biotechnology company developing drugs for the treatment of rare muscle diseases. It currently has no revenue. Its valuation is determined by the potential of its lead candidates, and future revenue is contingent on successful clinical trials and regulatory approval.
Edgewise Therapeutics is a biotech company developing drugs to treat rare muscle diseases. Its success depends on clinical trial results and scientific breakthroughs, not economic cycles. This overall market performance chart serves only as a backdrop for a company whose value is created in the laboratory and determined by its potential to help patients.
Edgewise Therapeutics is a clinical-stage biotechnology company developing small-molecule drugs for the treatment of rare muscle diseases. The company does not yet have sales revenue. This chart illustrates analysts' expectations for potential future sales of its drugs should they be successfully approved and launched.
%20sales%20of%20the%20company%20Edgewise%20Therapeutics&width=1500&height=450&colorIndex=53&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Edgewise-Therapeutics "Schedule of future (projected) sales of the company Edgewise Therapeutics")
Edgewise Therapeutics is a biotech company developing drugs to treat rare muscle diseases. This chart shows sales forecasts for the biotech sector. Is market growth expected due to new approaches to treating muscular dystrophy? This helps assess the overall scientific and commercial potential of the industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20&width=1500&height=450&colorIndex=54&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment "Schedule of future (projected) sales of companies in the market segment -")
Edgewise Therapeutics is a biotech company developing treatments for rare muscle diseases. Its value and prospects depend solely on clinical trial results and scientific progress. The overall economic trends reflected in this chart do not directly impact its core business or patient demand for treatment.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole "Schedule of future (predicted) sales of the market as a whole")
Edgewise Therapeutics is a biotechnology company developing small-molecule drugs to treat severe and rare muscle diseases. This chart reflects its financial performance at the clinical trial stage. Profitability is a future goal, and current metrics demonstrate the company's investment in research aimed at protecting and restoring muscle tissue.
Edgewise Therapeutics is a clinical-stage biotechnology company developing drugs for the treatment of rare neuromuscular diseases. The company has no revenue and is entirely focused on R&D. This chart reflects its current financial performance, with profitability being a long-term goal dependent on the success of its R&D and subsequent commercialization.
Edgewise Therapeutics is a biotech company developing drugs to treat rare muscle diseases. Its future depends on the success of clinical trials and raising funding. This total return chart reflects the investment climate and the market's willingness to invest in long-term, high-risk research.
Edgewise Therapeutics is a clinical-stage biotech company developing drugs to treat rare muscle diseases. Its small staff consists of scientists and clinicians. This graph shows how the team grows as its lead candidates advance through clinical trials, requiring expanded expertise and resources.
Edgewise Therapeutics is a biotech company developing oral medications for rare muscle diseases. Its activities are focused on scientific research and clinical trials. This graph shows the company's market share in the biotech industry, and its dynamics reflect its progress in drug development and competition for scientific talent.
Edgewise Therapeutics is a biopharmaceutical company developing small-molecule drugs for the treatment of severe and rare neuromuscular diseases. This chart shows the employment in the neurological pharmaceutical sector. Edgewise's innovative approach to protecting muscles from damage could offer a new standard of care for patients.
Edgewise Therapeutics is a biotech company developing treatments for rare muscle diseases. Growing its team of scientists and researchers is an investment in the future of medicine. Compared to the overall employment shown in this chart, Edgewise's hiring speaks not to the state of the economy, but to progress in the fight against severe genetic diseases.
Edgewise Therapeutics is a biotech company. This chart shows how the market values their scientific potential in muscle diseases. The entire value could be captured in a single promising development. The market cap per employee could be extremely high, reflecting investor expectations for a future blockbuster.
%20of%20the%20company%20Edgewise%20Therapeutics%20(EWTX)&width=1500&height=450&colorIndex=63&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Edgewise-Therapeutics-EWTX "Chart of market capitalization per employee (in thousands of dollars) of the company Edgewise Therapeutics (EWTX)")
Edgewise Therapeutics (EWTX) is a biotech company developing small-molecule drugs to treat rare muscle diseases (e.g., muscular dystrophies). It's an R&D-focused business. This chart shows the average market capitalization per employee in the sector. It helps assess the premium the market places on their scientific platform.
%20by%20market%20segment%20-%20&width=1500&height=450&colorIndex=64&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment "Market capitalization per employee (in thousands of dollars) by market segment -")
Edgewise Therapeutics is a biotech company developing drugs to treat rare muscle diseases. Its valuation is based on its scientific potential. The chart shows a high valuation per employee, which is typical for clinical biotechs, where investors are betting on the future success of a small but highly skilled scientific team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market "Market capitalization per employee (in thousands of dollars) for the overall market")
Edgewise Therapeutics is a clinical-stage biotech developing drugs to treat rare muscle diseases. This chart, like most biotech companies, shows the investment phase (loss per employee). It reflects how much capital the company burns per scientist to bring a drug to approval.
%20Chart%20Edgewise%20Therapeutics%20(EWTX)&width=1500&height=450&colorIndex=66&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Edgewise-Therapeutics-EWTX "Company Profit Per Employee (in thousands of dollars) Chart Edgewise Therapeutics (EWTX)")
Edgewise (EWTX) is a biotech R&D company (muscle diseases). This chart shows the benchmark for "Pharma" (R&D). The average profit per employee in this sector (venture R&D) is *negative*. This benchmark reflects the "burning" of money in the hopes of one or two mega-successes. The entire sector is an R&D race, spending billions on elite scientists.
%20in%20the%20market%20segment%20-%20&width=1500&height=450&colorIndex=67&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment "Chart of profit per employee (in thousands of dollars) in the market segment -")
Edgewise Therapeutics is a clinical-stage biotech company specializing in the treatment of muscular dystrophies (a competitor of SRPT). It's an R&D company. Like Dyne, this chart shows the operating loss per employee—the "cost" of conducting expensive clinical trials per research staff.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Edgewise Therapeutics is a biotech company developing drugs to treat muscle diseases. At the clinical stage, there is no revenue per employee. The timeline is important as an indicator of future potential: a successful drug could generate billions, leading to a colossal increase in revenue per employee.
&width=1500&height=450&colorIndex=69&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Sales-chart-per-company-employee-Edgewise-Therapeutics-EWTX "Sales chart per company employee Edgewise Therapeutics (EWTX)")
Edgewise Therapeutics (EWTX) is a clinical-stage biotech developing drugs to treat rare muscle diseases. This is pure R&D. This chart shows the average output in the sector. As with other R&D biotechs, this is a leading indicator of the effectiveness of R&D staffing to advance their developments through clinical trials.
EWTX (Edgewise Therapeutics) is a biotech company developing drugs to treat rare muscle diseases. Being in the clinical stage, the company has no sales revenue. This indicator reflects ongoing investment in the scientific team working on the development of future drugs.
Edgewise (EWTX) is a clinical-stage biotech developing drugs to treat rare muscle diseases, competing with Sarepta (SRPT). This chart shows the volume of short positions. Shorting is a direct bet that the company's clinical trials will fail or that its drug will perform worse than its competitors.
&width=1500&height=450&colorIndex=72&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Edgewise-Therapeutics-EWTX "Short Shares Chart for the Company Edgewise Therapeutics (EWTX)")
Edgewise Therapeutics (EWTX) is a biotech company developing oral medications for rare neuromuscular diseases (DMD). This chart aggregates short positions across the biotech sector. It reflects the high level of risk and investor skepticism surrounding clinical trials in this complex area.
Edgewise (EWTX) is a clinical-stage biotech (muscle diseases). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs. This pessimism, visible on the chart, deprives EWTX of access to the capital needed for expensive trials.
Edgewise Therapeutics (EWTX) is a biotech company focused on treating rare muscle diseases such as Duchenne muscular dystrophy. Their goal is to develop drugs that protect muscle fibers. This chart measures hype. It shows "overheated" (above 70) due to positive clinical trial data or "oversold" (below 30) due to delays or setbacks in R&D.
&width=1500&height=450&colorIndex=75&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Edgewise-Therapeutics-EWTX "RSI 14 indicator chart for the company's stock Edgewise Therapeutics (EWTX)")
Edgewise (EWTX) is a biotech company developing drugs to treat severe muscle disorders (myodystrophy). The RSI_14_Seg for "Pharma neurology" (biotech) shows the overall sentiment. The chart helps us understand: is EWTX's volatility a reaction to their trials or is the entire sector overheated?
Edgewise (EWTX) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Edgewise Therapeutics is a biotech company developing oral medications (tablets) for the treatment of rare muscular dystrophies. This chart shows the average 12-month forecast of analysts. It represents their collective speculative bet that the company's clinical trials will be successful and transform the market.
&width=1500&height=450&colorIndex=78&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-EWTX-Edgewise-Therapeutics "A chart showing analyst consensus forecasts for the expected stock price. EWTX (Edgewise Therapeutics)")
Edgewise Therapeutics is a biotech company developing a new class of oral medications (tablets) for the treatment of severe muscular dystrophies (Duchenne, Becker). This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the current share price and the consensus target price.
&width=1500&height=450&colorIndex=79&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-EWTX-Edgewise-Therapeutics "A chart showing the difference between the consensus forecast and the actual stock price. EWTX (Edgewise Therapeutics)")
Edgewise Therapeutics is a clinical-stage biopharmaceutical company developing drugs to treat serious muscle diseases (Duchenne and Becker muscular dystrophy). This chart shows general expectations for the neuroscience and muscle sectors. It reflects whether experts believe in this new approach to protecting muscles from damage.
Edgewise Therapeutics (EWTX) is a clinical-stage biopharmaceutical company focused on treating rare muscle diseases such as muscular dystrophy. This chart shows the overall risk appetite in the market. It serves as an indicator of the open or closed funding window for speculative biotechs seeking capital.
Edgewise Therapeutics is a clinical-stage biotech focused on developing oral (tablet-based) therapies for rare muscle diseases. This chart represents pure R&D investment. It likely reflects investor confidence in their scientific platform (targeted at muscle protection) and successful clinical data, rather than revenue.
Edgewise (EWTX) is a clinical-stage biotech focused on muscle diseases; the company is developing innovative oral (tablet-based) therapies for the treatment of muscular dystrophy (Becker, Duchenne). This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this niche (muscle) R&D focus (EWTX) differentiate it from the average pharma company?
Edgewise Therapeutics is a biotech company developing therapies for rare muscle diseases (Becker/Duchenne dystrophy) and the heart. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this scientific story, aimed at preserving muscle function, compares to overall economic trends.
